Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Theravance IPO Would Fund Phase III Telavancin Antibiotic Trials

This article was originally published in The Pink Sheet Daily

Executive Summary

Phase I data for telavancin indicates non-inferiority to standard of care therapy. Theravance also has a broad collaborative agreement with GSK for long-acting beta-2 agonists for the treatment of COPD. Former Merck CEO Roy Vagelos is chairman of Theravance.

You may also be interested in...



GSK/Theravance Target 2008 Phase III Start For Next-Gen Bronchodilators

Two compounds stemming from the collaboration given once daily were equivalent to salmeterol twice daily in Phase IIb clinical studies.

GSK/Theravance Target 2008 Phase III Start For Next-Gen Bronchodilators

Two compounds stemming from the collaboration given once daily were equivalent to salmeterol twice daily in Phase IIb clinical studies.

Theravance’s First NDA Is Antibiotic Telavancin

Firm is seeking approval of telavancin for complicated skin and skin structure infections caused by Gram-positive bacteria.

Topics

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel